Multifunctional nanocarriers

Advanced Drug Delivery Reviews

Volumn 64, Issue SUPPL., 2012, Pages 302-315

  Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Drug delivery; Drug targeting; Imaging; Intracellular drug delivery; Liposomes; Long circulating drug carriers; Micelles; Nanomedicine; Pharmaceutical carriers; Polymeric nanoparticles

Indexed keywords

CARRIER LOADING; CONTRAST MATERIAL; CURRENT STATUS; DIAGNOSTIC PROTOCOLS; DRUG CARRIER; DRUG RELEASE; DRUG-TARGETING; IMMUNOLIPOSOMES; IN-VIVO; INTRACELLULAR DRUG DELIVERY; MULTI-FUNCTIONAL NANOCARRIERS; NANO-EMULSIONS; NANOCARRIERS; PHYSIOLOGICAL CONDITION; POLYMERIC NANOPARTICLES; POSSIBLE FUTURES; PRECLINICAL DEVELOPMENT; TARGET RECOGNITION; USEFUL PROPERTIES; VASCULATURE;

BLOOD; DIAGNOSIS; DRUG DELIVERY; DRUG PRODUCTS; IMAGING TECHNIQUES; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MICELLES; NANOPARTICLES; POLYMERS;

SURFACE PROPERTIES;

ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL PENETRATING PEPTIDE; CISPLATIN; COPOLYMER; DNA; DOXORUBICIN; DRUG CARRIER; FENRETINIDE; FLUOROURACIL; GADOLINIUM PENTETATE; HYPERICIN; LIGAND; LIPOFECTIN; LIPOSOME; MACROGOL; METHOTREXATE; MITOMYCIN C; NANOCARRIER; NANOSPHERE; PACLITAXEL; PENTETATE INDIUM IN 111; POLOXAMER; POLY(ACRYLICAMIDE); POLYGLACTIN; POLYGLYCOLIDE POLYETHYLENE GLYCOL COPOLYMER; POLYLYSINE POLY(ETHYLENE OXIDE)COPOLYMER; POLYMER; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADSORPTION; ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; CELL PERMEABILIZATION; CELL PH; CELL TRANSPORT; CHEMICAL MODIFICATION; CLEARANCE; CYTOSOL; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG RETENTION; DRUG TRANSPORT; ENDOCYTOSIS; GENE TARGETING; HALF LIFE TIME; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; LONGEVITY; MICELLE; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPSONIZATION; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RNA BINDING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SOLUBILITY; SURFACE PROPERTY; TEMPERATURE SENSITIVITY; VIRAL GENE DELIVERY SYSTEM;

EID: 84870253445     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.031     Document Type: Review

References (266)

1. Pharmaceutical Particulate Carriers 1993, Marcel Dekker, New York. A. Rolland (Ed.).
2. Liposomes as Drug Carriers 1988, John Wiley and Sons, New York. G. Gregoriadis (Ed.).
3. Müller R. Carriers for Controlled Drug Delivery and Targeting 1991, CRC Press, Boca Raton.
4. Alonso M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 2004, 58:168-172.
5. Bernkop-Schnurch A., Walker G. Multifunctional matrices for oral peptide delivery. Crit. Rev. Ther. Drug Carr. Syst. 2001, 18:459-501.
6. van Vlerken L.E., Amiji M.M. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin. Drug Deliv. 2006, 3:205-216.
7. Torchilin V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul 1998, 15:1-19.
8. Stealth Liposomes 1995, CRC Press, Boca Raton. D. Lasic, F. Martin (Eds.).
9. Microparticulate Systems for the Delivery of Proteins and Vaccines 1996, Marcel Dekker, New York. S. Cohen, H. Bernstein (Eds.).
10. Trubetskoy V.S., Torchilin V.P. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 1995, 16:311-320.
11. Torchilin V.P. How do polymers prolong circulation times of liposomes?. J. Liposome Res. 1996, 6:99-116.
12. Moghimi S.M., Szebeni J. Stealth liposomes and long irculating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
13. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
15. Gabizon A. Liposome circulation time and targeting: implication for cancer chemotherapy. Adv. Drug Deliv. Rev. 1995, 16:285-294.
16. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-238.
17. Maruyama K., Yuda T., Okamoto A., Ishikura C., Kojima S., Iwatsuru M. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem. Pharm. Bull. (Tokyo) 1991, 39:1620-1622.
18. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
19. Allen T.M., Hansen C., Martin F., Redemann C., Young Y.A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
20. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:11460-11464.
21. Naper D.H. Polymeric Stabilization of Colloidal Dispersions 1983, Academic Press, New York.
22. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
23. Woodle M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids 1993, 64:249-262.
24. Allen T.M. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 1994, 13:285-309.
25. Chonn A., Semple S.C., Cullis P.R. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim. Biophys. Acta 1991, 1070:215-222.
26. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo: relation to circulation lifetimes. J. Biol. Chem. 1992, 267:18759-18765.
27. Lasic D.D., Martin F.G., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1991, 1070:187-192.
28. Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. Ther. Drug Carr. Syst. 1987, 3:123-193.
29. Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1992, 1103:94-100.
30. Needham D., McIntosh T.J., Lasic D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta 1992, 1108:40-48.
31. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
32. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 1995, 16:157-182.
33. Pang S.N.J. Final report on the safety assessment of polyethylene glycols (PEGs)-6, -8, -32, -75, -150, -14M, -20M. J. Am. Coll. Toxicol. 1993, 12:429-457.
34. Powell G.M. Polyethylene glycol. Handbook of Water Soluble Gums and Resins 1980, 1-31. McGraw-Hill, New York. R.L. Davidson (Ed.).
35. Yamaoka T., Tabata T., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 1994, 83:601-606.
36. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-417.
37. Torchilin V.P. Strategies and means for drug targeting: an overview. Biomedical Aspects of Drug Targeting 2002, 3-26. Kluwer Academic Publishers, Boston, Chapter 1. V.R. Muzykantov, V.P. Torchilin (Eds.).
38. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 1995, 16:141-155.
39. Torchilin V.P., Levchenko T.S., Whiteman K.R., Yaroslavov A.A., Tsatsakis A.M., Rizos A.K., Michailova E.V., Shtilman M.I. Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 2001, 22:3035-3044.
40. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., Veronese F.M. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 1995, 6:62-69.
41. Ranucci E., Spagnoli G., Sartore L., Ferruti P. Synthesis and molecular weight characterization of low molecular weight end-functionalized poly(4-acryloymorpholine). Macromol. Chem. Phys. 1994, 195:3469-3479.
42. Sartore L., Ranucci E., Ferruti P., Caliceti P., Schiavon O., Veronese F.M. Low molecular weight end-functionalized poly(N-vinylpyrrolidone) for the modifications of polypeptide aminogroups. J. Bioact. Compat. Polym. 1994, 9:411-427.
43. Woodle M.C., Engbers C.M., Zalipsky S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 1994, 5:493-496.
44. Maruyama K., Okuizumi S., Ishida O., Yamauchi H., Kikuchi H., Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 1994, 111:103-107.
45. Takeuchi H., Kojima H., Toyoda T., Yamamoto H., Hino T., Kawashima Y. Prolonged circulation time of doxorubicin-loaded liposomes coated with a modified polyvinyl alcohol after intravenous injection in rats. Eur. J. Pharm. Biopharm. 1999, 48:123-129.
46. Torchilin V.P., Trubetskoy V.S., Whiteman K.R., Caliceti P., Ferruti P., Veronese F.M. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J. Pharm. Sci. 1995, 84:1049-1053.
47. Moghimi S.M., Porter C.J.H., Illum L., Davis S.S. The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres. Int. J. Pharm. 1991, 68:121-126.
48. Illum L., Davis S.S. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J. Pharm. Sci. 1983, 72:1086-1089.
49. de Sousa Delgado A., Leonard M., Dellacherie E. Surface modification of polystyrene nanoparticles using dextrans and dextran-POE copolymers: polymer adsorption and colloidal characterization. J. Biomater. Sci., Polym. Ed. 2000, 11:1395-1410.
50. Krause H.J., Schwartz A., Rohdewald P. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm. 1985, 27:145-155.
51. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V.S., Torchilin V.P., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
52. Gref R., Domb A., Quellec P., Blunk T., Muller R.H., Verbavatz J.M., Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16:215-233.
53. Harper G.R., Davies M.C., Davis S.S., Tadros T.F., Taylor D.C., Irving M.P., Waters J.A. Steric stabilization of microspheres with grafted polyethylene oxide reduces phagocytosis by rat Kupffer cells in vitro. Biomaterials 1991, 12:695-700.
54. Muller M., Voros J., Csucs G., Walter E., Danuser G., Merkle H.P., Spencer N.D., Textor M. Surface modification of PLGA microspheres. J. Biomed. Mater. Res. A 2003, 66:55-61.
55. Peracchia M.T., Fattal E., Desmaele D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 1999, 60:121-128.
56. Calvo P., Gouritin B., Chacun H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J.P., Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 2001, 18:1157-1166.
57. Bhadra D., Bhadra S., Jain S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003, 257:111-124.
58. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
59. Illum L., Church A.E., Butterworth M.D., Arien A., Whetstone J., Davis S.S. Development of systems for targeting the regional lymph nodes for diagnostic imaging: in vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm. Res. 2001, 18:640-645.
60. Gupta A.K., Curtis A.S. Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J. Mater. Sci., Mater. Med. 2004, 15:493-496.
61. Zhang F., Kang E.T., Neoh K.G., Huang W. Modification of gold surface by grafting of poly(ethylene glycol) for reduction in protein adsorption and platelet adhesion. J. Biomater. Sci., Polym. Ed. 2001, 12:515-531.
62. Patel H., Moghimi S. Tissue specific opsonins and phagocytosis of liposomes. Targeting of Drugs - Optimization Strategies 1990, 87. Plenum Press, New York. G. Gregoriadis, A. Allison, G. Poste (Eds.).
63. Porter C.J.H., Moghimi S.M., Illum L.L., Davis S.S. The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 1992, 305:62-66.
64. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3762.
65. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., Yuan F., Jain R.K. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999, 59:4129-4135.
66. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
67. Torchilin V.P., Shtilman M.I., Trubetskoy V.S., Whiteman K., Milstein A.M. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim. Biophys. Acta 1994, 1195:181-184.
68. Jamshaid M., Farr S.J., Kearney P., Kellaway I.W. Poloxamer sorption on liposomes: comparison with polystyrene latex and influence on solute efflux. Int. J. Pharm. 1988, 48:125-131.
69. Woodle M.C., Newman M.S., Martin F.J. Liposome leakage and blood circulation: comparison of absorbed block copolymers with covalent attachment of PEG. Int. J. Pharm. 1992, 88:327-334.
70. Murad K.L., Mahany K.L., Brugnara C., Kuypers F.A., Eaton J.W., Scott M.D. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol). Blood 1999, 93:2121-2127.
71. Scott M.D., Murad K.L. Cellular camouflage: fooling the immune system with polymers. Curr. Pharm. Des. 1998, 4:423-438.
72. Scott M.D., Chen A.M. Beyond the red cell: pegylation of other blood cells and tissues. Transfus. Clin. Biol. 2004, 11:40-46.
73. Kellam B., De Bank P.A., Shakesheff K.M. Chemical modification of mammalian cell surfaces. Chem. Soc. Rev. 2003, 32:327-337.
74. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6949-6953.
75. Huang S.K., Stauffer P.R., Hong K., Guo J.W., Philips T.L., Huang A., Papahadjopoulos D. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994, 54:2186-2191.
76. Gabizon, Catane R., Uziely B., Kauffman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
77. Boman N.L., Masin D., Mayer L.D., Cullis P.R., Bally M.B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994, 54:2830-2833.
78. Allen T.M., Mehra T., Hansen C., Chin Y.C. Stealth liposomes: an improved sustained release system for 1-beta-d-arabinofuranosylcytosine. Cancer Res. 1992, 52:2431-2439.
79. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005, 10:205-214.
80. Ewer M.S., Martin F.J., Henderson C., Shapiro C.L., Benjamin R.S., Gabizon A. Cardiac safety of liposomal anthracyclines. Semin. Oncol. 2004, 31(6 Suppl 13):161-181.
81. Allen T.M., Hansen C.B., de Menenez D.E.L. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev. 1995, 16:267-284.
82. Hwang K.J. Liposome pharamacokinetics. Liposomes: from Biophysics to Therapeutics 1987, 109-156. Marcel Dekker, New York. M. Ostro (Ed.).
83. Torchilin V.P. Immobilization of specific proteins on liposome surface: systems for drug targeting. Liposome Technology 1984, vol. 3:75-94. CRC Press, Boca Raton. G. Gregoriadis (Ed.).
84. Torchilin V.P. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carr. Syst. 1985, 2:65-115.
85. Torchilin V.P., Omelyanenko V.G., Klibanov A.L., Mikhailov A.V., Goldansky V.I., Smirnov V.N. Incorporation of hydrophilic protein modified with hydrophobic agent into liposome membrane. Biochim. Biophys. Acta 1981, 602:511-521.
86. Torchilin V.P., Klibanov A.L., Smirnov V.N. Phosphatidyl inositol may serve as the hydrophobic anchor for immobilization of proteins on liposome surface. FEBS Lett. 1982, 138:117-120.
87. Weissig V., Lasch J., Klibanov A.L., Torchilin V.P. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett. 1986, 202:86-90.
88. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target. 2004, 12:461-471.
89. Balthasar S., Michaelis K., Dinauer N., von Briesen H., Kreuter J., Langer K. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 2005, 26:2723-2732.
90. Thomas T.P., Patri A.K., Myc A., Myaing M.T., Ye J.Y., Norris T.B., Baker J.R. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 2004, 5:2269-2274.
91. Klibanov A.L. Antibody-mediated targeting of PEG-coated liposomes. Long-circulating Liposomes: Old Drugs, New Therapeutics 1998, 269. Springer Verlag, Berlin. M.C. Woodle, G. Storm (Eds.).
92. Torchilin V.P., Klibanov A.L., Huang L., O'Donnell S., Nossiff N.D., Khaw B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 1992, 6:2716-2719.
93. Benhar I., Padlan E.A., Jung S.H., Lee B., Pastan I. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12051-12055.
94. Khaw B.A., Klibanov A.L., O'Donnell S.M., Saito T., Nossiff N., Slinkin M.A., Newell J.B., Strauss H.W., Torchilin V.P. Gamma imaging with negatively charge-modified monoclonal antibody: modification with synthetic polymers. J. Nucl. Med. 1991, 32:1742-1752.
95. Blume G., Cevc, Crommelin M.D., Bakker-Woudenberg I.A., Kluft C., Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1993, 1149:180-184.
96. Torchilin V.P., Levchenko T.S., Lukyanov A.N., Khaw B.A., Klibanov A.L., Rammohan R., Samokhin G.P., Whiteman K.R. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 2001, 1511:397-411.
97. Zalipsky S., Gittelman J., Mullah N., Qazen M.M., Harding J. Biologically active ligand-bearing polymer-grafted liposomes. Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems 1998, 131-139. Plenum, New York. G. Gregoriadis (Ed.).
98. Torchilin V.P., Rammohan R., Weissig V., Khaw B.A., Klibanov A.L., Samokhin G.P. Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials 2000, 217-218. Controlled Release Society, Inc., Paris.
99. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6039-6044.
100. Zalipsky S., Mullah N., Harding J.A., Gittelman J., Guo L., DeFrees S.A. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug. Chem. 1997, 8:111-118.
101. Wong J., Kuhl T.L., Israelachvili J.N., Mullah N., Zalipsky S. Direct measurement of a tethered ligand-receptor interaction potential. Science 1997, 275:820-822.
102. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 1999, 10:289-298.
103. DeFrees S.A., Phillips L., Guo L., Zalipsky S. Sialyl Lewis x liposomes as a multivalent ligand and inhibitor of E-selectinmediated cellular adhesion. J. Am. Chem. Soc. 1996, 118:6101-6104.
104. Yoshioka H. Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. Biomaterials 1991, 12:861-864.
105. Sapra P., Allen T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002, 62:7190-7194.
106. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao R., Nielsen U.B., Marks J.D., Papahadjopoulos D., Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 2001, 74:95-113.
107. Kamps J.A., Koning G.A., Velinova M.J., Morsel H.W., Wilkens M., Gorter A., Donga J., Scherphof G.L. Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J. Drug Target. 2000, 8:235-245.
108. Lukyanov A.N., Elbayoumi T.A., Chakilam A.R., Torchilin V.P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 2004, 100:135-144.
109. Raffaghello L., Pagnan G., Pastorino F., Cosimo E., Brignole C., Marimpietri D., Bogenmann E., Ponzoni M., Montaldo P.G. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett. 2003, 197:151-155.
110. Marty C., Schwendener R.A. Cytotoxic tumor targeting with scFv antibody-modified liposomes. Methods Mol. Med. 2005, 109:389-402.
111. Mastrobattista E., Koning G.A., van Bloois L., Filipe A.C., Jiskoot W., Storm G. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J. Biol. Chem. 2002, 277:27135-27143.
112. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004, 56:1649-1959.
113. Olivier J.C., Huertas R., Lee H.J., Calon F., Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm. Res. 2002, 19:1137-1143.
114. Kato K., Itoh C., Yasukouchi T., Nagamune T. Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(ethylene glycol) derivatives. Biotechnol. Prog. 2004, 20:897-904.
115. Hatakeyama H., Akita H., Maruyama K., Suhara T., Harashima H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm. 2004, 281:25-33.
116. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 2001, 18:1042-1048.
117. Derycke A.S., De Witte P.A. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int. J. Oncol. 2002, 20:181-187.
118. Gijsens A., Derycke A., Missiaen L., De Vos D., Huwyler J., Eberle A., de Witte P. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int. J. Cancer 2002, 101:78-85.
119. Iinuma H., Maruyama K., Okinaga K., Sasaki K., Sekine T., Ishida O., Ogiwara N., Johkura K., Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 2002, 99:130-137.
120. Joshee N., Bastola D.R., Cheng P.W. Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum. Gene Ther. 2002, 13:1991-2004.
121. Xu L., Huang C.C., Huang W., Tang W.H., Rait A., Yin Y.Z., Cruz I., Xiang L.M., Pirollo K.F., Chang E.H. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 2002, 1:337-346.
122. Tan P.H., Manunta M., Ardjomand N., Xue S.A., Larkin D.F., Haskard D.O., Taylor K.M., George A.J. Antibody targeted gene transfer to endothelium. J. Gene Med. 2003, 5:311-323.
123. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14164-14169.
124. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:5572-5576.
125. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 1994, 269:3198-3204.
126. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 2002, 54:675-693.
127. Gabizon A., Shmeeda H., Horowitz A.T., Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 2004, 56:1177-1192.
128. Ni S., Stephenson S.M., Lee R.J. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res. 2002, 22:2131-2135.
129. Pan X.O., Wang H., Lee R.J. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res. 2003, 20:417-422.
130. Stephenson S.M., Yang W., Stevens P.J., Tjarks W., Barth R.F., Lee R.J. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res. 2003, 23:3341-3345.
131. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 2002, 51:153-162.
132. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89:1452-1464.
133. Park E.K., Lee S.B., Lee Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 2005, 26:1053-1061.
134. Zhang Y., Kohler N., Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002, 23:1553-1561.
135. Choi H., Choi S.R., Zhou R., Kung H.F., Chen I.W. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol. 2004, 11:996-1004.
136. Choi Y., Baker J.R. Targeting cancer cells with DNA-assembled dendrimers: a mix and match strategy for cancer. Cell Cycle 2005, 4:669-671.
137. Majoros I.J., Thomas T.P., Mehta C.B., Baker J.R. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem. 2005, 48:5892-5899.
138. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108:780-789.
139. Dagar S., Krishnadas A., Rubinstein I., Blend M.J., Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J. Control. Release 2003, 91:123-133.
140. Schiffelers R.M., Koning G.A., ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., Kok R.J., Molema G., Storm G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 2003, 91:115-122.
141. Lestini B.J., Sagnella S.M., Xu Z., Shive M.S., Richter N.J., Jayaseharan J., Case A.J., Kottke-Marchant K., Anderson J.M., Marchant R.E. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Control. Release 2002, 78:235-247.
142. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., Taki T., Shuto S., Matsuda A., Oku N. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 2002, 520:167-170.
143. Guo X., Szoka F.C. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug. Chem. 2001, 12:291-300.
144. Boomer J.A., Thompson D.H. Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications. Chem. Phys. Lipids 1999, 99:145-153.
145. Zalipsky S., Qazen M., Walker J.A., Mullah N., Quinn Y.P., Huang S.K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem. 1999, 10:703-707.
146. Kratz F., Beyer U., Schutte M.T. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carr. Syst. 1999, 16:245-288.
147. Zhang J.X., Zalipsky S., Mullah N., Pechar M., Allen T.M. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol. Res. 2004, 49:185-198.
148. Roux E., Francis M., Winnik F.M., Leroux J.C. Polymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugs. Int. J. Pharm. 2002, 242:25-36.
149. Simoes S., Moreira J.N., Fonseca C., Duzgunes N., de Lima M.C. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 2004, 56:947-965.
150. Roux E., Passirani C., Scheffold S., Benoit J.P., Leroux J.C. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J. Control. Release 2004, 94:447-451.
151. Leroux J., Roux E., Le Garrec D., Hong K., Drummond D.C. N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J. Control. Release 2001, 72:71-84.
152. Roux E., Stomp R., Giasson S., Pezolet M., Moreau P., Leroux J.C. Steric stabilization of liposomes by pH-responsive N-isopropylacrylamide copolymer. J. Pharm. Sci. 2002, 91:1795-1802.
153. Sudimack J.J., Guo W., Tjarks W., Lee R.J. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim. Biophys. Acta 2002, 1564:31-37.
154. Lee E.S., Na K., Bae Y.H. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 2003, 91:103-113.
155. Lee E.S., Shin H.J., Na K., Bae Y.H. Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization. J. Control. Release 2003, 90:363-374.
156. Turk M.J., Reddy J.A., Chmielewski J.A., Low P.S. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 2002, 1559:56-68.
157. Kakudo T., Chaki S., Futaki S., Nakase I., Akaji K., Kawakami T., Maruyama K., Kamiya H., Harashima H. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004, 43:5618-5628.
158. Shi G., Guo W., Stephenson S.M., Lee R.J. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J. Control. Release 2002, 80:309-319.
159. Paleos C.M., Tsiourvas D., Sideratou Z., Tziveleka L. Acid-and salt-triggered multifunctional poly(propylene imine) dendrimer as a prospective drug delivery system. Biomacromolecules 2004, 5:524-529.
160. Sawant R.M., Hurley J.P., Huang Z., Szoka F.C., Torchilin V.P. Proceedings of the 32nd International Symposium on Controlled Release of Bioactive Materials 2005, Controlled Release Society, Inc., Miami.
161. Varga C.M., Wickham T.J., Lauffenburger D.A. Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol. Bioeng. 2000, 70:593-605.
162. Roth J.A., Swisher S.D., Merritt J.A., Lawrence D.D., Kemp B.L., Carrasco C.H., El-Naggar A.K., Fossella F.V., Glisson B.S., Hong W.K., Khurl F.R., Kurie J.M., Nesbitt J.C., Pisters K., Putnam J.B., Schrump D.S., Shin D.M., Walsh G.L. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol. 1998, 25(Suppl. 8):33-37.
163. Lisziewicz J., Sun D., Lisziewicz A., Gallo R.C. Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther. 1995, 2:218-222.
164. Farhood H., Serbina N., Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1995, 1235:289-295.
165. Scheule R.K., St George J.A., Bagley R.G., Marshall J., Kaplan J.M., Akita G.Y., Wang K.X., Lee E.R., Harris D.J., Jiang C., Yew N.S., Smith A.E., Cheng S.H. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 1997, 8:689-707.
166. Filion M.C., Phililips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta 1997, 1329:345-356.
167. Tang F., Hughes J.A. Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. Bioconjug. Chem. 1999, 10:791-796.
168. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35:5616-5623.
169. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7413-7417.
170. Wu G.Y., Wu C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 1987, 262:4429-4432.
171. Elouahabi A., Ruysschaert J.M. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. 2005, 11:336-347.
172. Kunath K., von Harpe A., Fischer D., Petersen H., Bickel U., Voigt K., Kissel T. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release 2003, 89:113-125.
173. Sakurai F., Inoue R., Nishino Y., Okuda A., Matsumoto O., Taga T., Yamashita F., Takakura Y., Hashida M. Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. J. Control. Release 2000, 66:255-269.
174. Ogris M., Steinlein P., Carotta S., Brunner S., Wagner E. DNA/polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSci. 2001, 3:E21.
175. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., Ramsey P., Martin M., Felgner P.L. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 1994, 269:2550-2561.
176. Koltover I., Salditt T., Radler J.O., Safinya C.R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 1998, 281:78-81.
177. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7297-72301.
178. 2+ sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. J. Gene Med. 2001, 3:153-164.
179. Pollard H., Remy J.S., Loussouarn G., Demolombe S., Behr J.P., Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J. Biol. Chem. 1998, 273:7507-7511.
180. Branden L.J., Mohamed A.J., Smith C.I. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol. 1999, 17:784-787.
181. Salem A.K., Searson P.C., Leong K.W. Multifunctional nanorods for gene delivery. Nat. Matters 2003, 2:668-671.
182. Immobilized Enzymes in Medicine 1991, 206. Springer-Verlag, Berlin. V.P. Torchilin (Ed.).
183. Torchilin V.P., Zhou F., Huang L. pH-sensitive liposomes. J. Liposome Res. 1993, 3:201-255.
184. Sheff D. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev. 2004, 56:927-930.
185. Shalaev E.Y., Steponkus P.L. Phase diagram of 1,2-dioleoylphosphatidylethanolamine (DOPE):water system at subzero temperatures and at low water contents. Biochim. Biophys. Acta 1999, 1419:229-247.
186. Gaspar M., Perez-Soler R., Cruz M.E. Biological characterization of l-asparaginase liposomal formulations. Cancer Chemother. Pharmacol. 1996, 38:373-377.
187. Stanimirovic D.B., Markovic M., Micic D.V., Spatz M., Mrsulja B.B. Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion 'oxidative stress' in gerbil brain. Neurochem. Res. 1994, 19:1473-1478.
188. Heeremans J.L., Prevost R., Bekkers M.E., Los P., Emeis J.J., Kluft C., Crommelin D.J. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb. Haemost. 1995, 73:488-494.
189. Rubas W., Supersaxo A., Weder H.G., Hartmann H.R., Hengartner H., Schott H., Schwendener R. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int. J. Cancer 1986, 37:149-154.
190. Geisert E.E., Del Mar N.A., Owens J.L., Holmberg E.G. Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes. Neurosci. Lett. 1995, 184:40-43.
191. Bae Y., Nishiyama N., Fukushima S., Koyama H., Yasuhiro M., Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 2005, 16:122-130.
192. Jeong J.H., Kim S.W., Park T.G. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug. Chem. 2003, 14:473-479.
193. Lukyanov A.N., Hartner W.C., Torchilin V.P. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J. Control. Release 2004, 94:187-193.
194. Hafez I.M., Maurer N., Cullis P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001, 8:1188-1196.
195. Wang J., Mongayt D., Torchilin V.P. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J. Drug Target. 2005, 13:73-80.
196. Lee E.S., Na K., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 2005, 5:325-329.
197. Yessine M.A., Leroux J.C. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv. Drug Deliv. Rev. 2004, 56:999-1021.
198. Chen G., Hoffman A.S. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. Nature 1995, 373:49-52.
199. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
200. Hallbrink M., Floren A., Elmquist A., Pooga M., Bartfai T., Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001, 1515:101-109.
201. Ruben S., Perkins A., Purcell R., Joung K., Sia R., Burghoff R., Haseltine W.A., Rosen C.A. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol. 1989, 63:1-8.
202. Siomi H., Shida H., Maki M., Hatanaka M. Effects of a highly basic region of human immunodeficiency virus TAT protein on nucleolar localization. J. Virol. 1990, 64:1803-1807.
203. Weeks K.M., Ampe C., Schultz S.C., Steitz T.A., Crothers D.M. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 1990, 249:1281-1285.
204. Schwarze S.R., Hruska K.A., Dowdy S.F. The third helix of the Antennapedia homeodomain translocates through biological membranes. Trends Cell Biol. 2000, 10:290-295.
205. Derossi D., Joliot A.H., Chassaing G., Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 26:10444-10450.
206. Elliott G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997, 88:223-233.
207. Pooga M., Hallbrink M., Zorko M., Langel U. Cell penetration by transportan. FASEB J. 1998, 12:67-77.
208. Oehlke J., Scheller A., Wiesner B., Krause E., Beyermann M., Klauschenz E., Melzig M., Bienert M. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1998, 1414:127-139.
209. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004, 10:310-315.
210. Rothbard J.B., Jessop T.C., Lewis R.S., Murray B.A., Wender P.A. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 2004, 126:9506-9507.
211. Kaufman C.L., Williams M., Ryle L.M., Smith T.L., Tanner M., Ho C. Superparamagnetic iron oxide particles transactivator protein-fluorescein isothiocyanate particle labeling for in vivo magnetic resonance imaging detection of cell migration: uptake and durability. Transplantation 2003, 76:1043-1046.
212. Liu J., Zhang Q., Remsen E.E., Wooley K.L. Nanostructured materials designed for cell binding and transduction. Biomacromolecules 2001, 2:362-368.
213. Dodd C.H., Hsu H.C., Chu W.J., Yang P., Zhang H.G., Mountz J.D., Zinn K., Forder J., Josephson L., Weissleder R., Mountz J.M., Mountz J.D. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J. Immunol. Methods 2001, 256:89-105.
214. Tkachenko A.G., Xie H., Liu Y., Coleman D., Ryan J., Glomm W.R., Shipton M.K., Franzen S., Feldheim D.L. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 2004, 15:482-490.
215. Torchilin V.P., Rammohan R., Weissig V., Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8786-8791.
216. Levchenko T.S., Rammohan R., Volodina N., Torchilin V.P. Tat peptide-mediated intracellular delivery of liposomes. Methods Enzymol. 2003, 372:339-349.
217. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1972-1977.
218. Tseng Y.L., Liu J.J., Hong R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol. Pharmacol. 2002, 62:864-872.
219. Marty C., Meylan C., Schott H., Ballmer-Hofer K., Schwendener R.A. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell. Mol. Life Sci. 2004, 61:1785-1794.
220. Handbook of Targeted Delivery of Imaging Agents 1995, CRC Press, Boca Raton. V.P. Torchilin (Ed.).
221. Sullivan D.C., Ferrari M. Nanotechnology and tumor imaging: seizing an opportunity. Mol. Imaging 2004, 3:364-369.
222. Morawski A.M., Lanza G.A., Wickline S.A. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr. Opin. Biotechnol. 2005, 16:89-92.
223. Tilcock C., Unger E., Cullis P., MacDougall P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 1989, 171:77-80.
224. Kabalka G., Davis M., Holmberg E., Maruyama K., Huang L. Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver. Magn. Res. Imaging 1991, 9:373-377.
225. Phillips W.T., Goins B. Targeted delivery of imaging agents by liposomes. Handbook of Targeted Delivery of Imaging Agents 1995, 149-173. CRC Press, Boca Raton. V.P. Torchilin (Ed.).
226. Tilcock C. Liposomal paramagnetic magnetic resonance contrast agents. Liposome Technology 1993, vol. 2:65-87. CRC Press, Boca Raton, FL. 2nd ed. G. Gregoriadis (Ed.).
227. Schwendener R., Wurthrich R., Duewell S., Wehrli E., von Schulthess G. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest. Radiol. 1990, 23:922-932.
228. Torchilin V.P., Trubetskoy V.S. In vivo visualizing of organs and tissues with liposomes. J. Liposome Res. 1995, 5:795-812.
229. Torchilin V.P. Surface-modified liposomes in gamma- and MR-imaging. Adv. Drug Deliv. Rev. 1997, 24:301-313.
230. Kabalka G.W., Davis M.A., Moss T.H., Buonocore E., Hubner K., Holmberg E., Maruyama K., Huang L. Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn. Reson. Med. 1991, 19:406-415.
231. Grant C.W.M., Karlik S., Florio E. A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn. Reson. Med. 1989, 11:236-243.
232. Glogard C., Stensrud G., Hovland G., Fossheim S.L., Klaveness J. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. Int. J. Pharm. 2002, 233:131-140.
233. Unger E., Cardenas D., Zerella A., Fajardo L.L., Tilcock C. Biodistribution and clearance of liposomal gadolinium-DTPA. Invest. Radiol. 1990, 25:638-644.
234. Barsky D., Putz B., Schulten K., Magin R.L. Theory of paramagnetic contrast agents in liposome systems. Magn. Reson. Med. 1992, 21:1-13.
235. Putz B., Barsky D., Schulten K. Mechanisms of liposomal contrast agents in magnetic resonance imaging. J. Liposome Res. 1994, 4:771-808.
236. Schwendener R.A. Liposomes as carriers for paramagnetic gadolinium chelates as organ specific contrast agents for magnetic resonance imaging (MRI). J. Liposome Res. 1994, 4:837-855.
237. Enoch H.G., Strittmatter P. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:145-149.
238. Davis S.S., Illum L., Moghimi S.M., Davies M.C., Porter C.J.H., Miur I.S., Brindley A., Christy N.M., Norman M.N., Williams P., Dunn S.E. Microspheres for targeting drugs to specific body sites. J. Control. Release 1993, 24:157-163.
239. Torchilin V.P. Polymeric contrast agents for medical imaging. Curr. Pharm. Biotechnol. 2000, 1:183-215.
240. Trubetskoy V.S., Torchilin V.P. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes. J. Liposome Res. 1994, 4:961-980.
241. Torchilin V.P. Novel polymers in microparticulate diagnostic agents. Chemtech 1999, 29:27-34.
242. Trubetskoy V.S., Torchilin V.P. Polyethyleneglycol based micelles as carriers of therapeutic and diagnostic agents. STP Pharma Sci. 1996, 6:79-86.
243. Torchilin V.P., Trubetskoy V.S., Wolf G.L. Magnetic resonance imaging of lymph nodes with GD-containing liposomes. Handbook of Targeted Delivery of Imaging Agents 1995, 403-413. CRC Press, Boca Raton. V.P. Torchilin (Ed.).
244. Patel H., Boodle C., Vaughan-Jones R. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim. Biophys. Acta 1984, 801:76-86.
245. Hirano K., Hunt A. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J. Pharm. Sci. 1985, 74:915-921.
246. Unger E., Winokur T., MacDougall P., Rosenblum J., Clair M., Gatenby R., Tilcock C. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology 1989, 171:81-85.
247. Schwendener R., Wurthrich R., Duewell S., Wehrli E., von Schulthess G. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest. Radiol. 1990, 23:922-932.
248. Torchilin V.P., Trubetskoy V.S., Narula J., Khaw B.A. PEG-modified liposomes for gamma- and magnetic resonance imaging. Stealth Liposomes 1995, 225-231. CRC Press, Boca Raton. F. Martin, D. Lasic (Eds.).
249. Trubetskoy V., Cannillo J., Milstein A., Wolf G., Torchilin V.P. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn. Reson. Imaging 1995, 13:31-37.
250. Torchilin V.P. Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. Q. J. Nucl. Med. 1997, 41:141-153.
251. Trubetskoy V.S., Frank-Kamenetsky M.D., Whiteman K.R., Wolf G.L., Torchilin V.P. Stable polymeric micelles: lymphangiographic contrast media for gamma scintigraphy and magnetic resonance imaging. Acad. Radiol. 1996, 3:232-238.
252. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73:137-172.
253. Torchilin V.P., Klibanov A.L. Coupling and labeling of phospholipids. Phospholipid Handbook 1993, 293-322. Marcel Dekker, New York. G. Cevc (Ed.).
254. Torchilin V.P., Weissig V., Martin F.J., Heath T.D. Surface modifications of liposomes. Liposomes 2003, 193-230. Oxford University Press, Oxford UK. V.P. Torchilin, V. Weissig (Eds.).
255. Klibanov A.L., Torchilin V.P., Zalipsky S. Long-circulating sterically protected liposomes. Liposomes 2003, 231. Oxford University Press, Oxford UK. V.P. Torchilin, V. Weissig (Eds.).
256. Dunnick J.K., McDougall I.R., Aragon S., Cons M.L., Kriss T.P. Vesicle interactions with polyamino acids and antibody: in vitro and in vivo studies. J. Nucl. Med. 1975, 16:483-487.
257. Leserman L.D., Barbet J., Kourilsky F., Weinstein J.N. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 1980, 288:602-604.
258. Martin F.S., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 1982, 257:286-288.
259. Heath T.D., Robertson D., Birbeck M.S.C., Davies A.I.S. Covalent attachment of horseradish peroxidase to the outer surface of liposomes. Biochim. Biophys. Acta 1980, 599:42-62.
260. Kung V.T., Redemann C.T. Synthesis of carboxyacyl derivatives of phosphatidylethanolamine and use as an efficient method for conjugation of protein to liposomes. Biochim. Biophys. Acta 1986, 862:435-439.
261. Bogdanov A.A., Klibanov A.L., Torchilin V.P. Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydroxysulfosuccinimide. FEBS Lett. 1988, 231:381-384.
262. Weissig V., Gregoriadis G. Coupling of aminogroup-bearing ligands to liposomes. Liposome Technology 1992, vol. 3:231-248. CRC Press Inc, Boca Raton. 2nd edition. G. Gregoriadis (Ed.).
263. Weissig V., Lasch J., Gregoriadis G. Covalent binding of peptides at liposome surfaces. Pharmazie 1990, 45:849-850.
264. Nobs L., Buchegger F., Gurny R., Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 2004, 93:1980-1992.
265. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1991, 1062:142-148.
266. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1995, 1234:74-80.